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ABSTRACT
TSPX is a tumor suppressor gene located at Xp11.22, a prostate cancer 
susceptibility locus. It is ubiquitously expressed in most tissues but frequently 
downregulated in various cancers, including lung, brain, liver and prostate cancers. 
The C-terminal acidic domain (CAD) of TSPX is crucial for the tumor suppressor 
functions, such as inhibition of cyclin B/CDK1 phosphorylation and androgen receptor 
transactivation. Currently, the exact role of the TSPX CAD in transcriptional regulation 
of downstream genes is still uncertain. Using different variants of TSPX, we showed 
that overexpression of either TSPX, that harbors a CAD, or a CAD-truncated variant 
(TSPX[∆C]) drastically retarded cell proliferation in a prostate cancer cell line 
LNCaP, but cell death was induced only by overexpression of TSPX. Transcriptome 
analyses showed that TSPX or TSPX[∆C] overexpression downregulated multiple 
cancer-drivers/oncogenes, including MYC and MYB, in a CAD-dependent manner and 
upregulated various tumor suppressors in a CAD-independent manner. Datamining 
of transcriptomes of prostate cancer specimens in the Cancer Genome Atlas (TCGA) 
dataset confirmed the negative correlation between the expression level of TSPX and 
those of MYC and MYB in clinical prostate cancer, thereby supporting the hypothesis 
that the CAD of TSPX plays an important role in suppression of cancer-drivers/
oncogenes in prostatic oncogenesis.
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INTRODUCTION
Prostate cancer is one of the leading cancer in the 
world [1]; more than 200,000 cases are newly diagnosed 
every year in the United States [2]. The molecular 
mechanisms associated with prostate cancer development 
are complex and still largely unknown, although 
various susceptibility loci/SNPs have been associated 
with either the familial or sporadic prostate cancer 
[3, 4]. Recent studies have suggested the involvements 
of various X-linked tumor suppressors in the prostate 
cancer development [5–7]. Since men have only a single 
X-chromosome, any inactivating mutation(s) on the 
X-linked tumor suppressor genes could predispose men 
for cancer development [5–7]. Indeed, a prostate cancer 
susceptibility locus (loci) has been mapped on Xp11.2 
associated with the SNP rs5945572 [8], adjacent of which 
multiple tumor suppressor genes, including FOXP3 
and AMER1 (also known as WTX and FAM123B), are 
located [7, 9, 10]. FOXP3 is frequently downregulated 
or inactivated by a mutation(s) in prostate cancer, and 
reactivation of FOXP3 expression suppresses cancer 
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growth [10, 11]. Mutations in the AMER1 gene are 
frequently detected in male colorectal cancer [12], 
although its status with prostate cancer is uncertain. 
Hence, alterations of X-linked genes, particularly tumor 
suppressors, could play important roles in prostate cancer 
initiation and progression.
The TSPY homologue on the X chromosome 
(TSPX, also known as CDA1, DENTT, and TSPYL2) 
is another tumor suppressor gene located at the Xp11.2 
locus. TSPX is ubiquitously expressed in normal tissues 
(research reports [13, 14], and data portals; GTEx [15] 
and BioGPS [16]), but it is frequently downregulated in 
various types of cancer, including lung cancer, glioma, 
and liver cancer [17–19]. It has been demonstrated that 
overexpression of TSPX in a lung carcinoma cell line 
A549 and a cervical cancer cell line HeLa resulted in 
retardation of cell proliferation [17, 20]. TSPX upregulated 
CDKN1A gene by activating TP53-pathway in HeLa cells 
[20], and/or by suppressing NTRK3 proto-oncogene (also 
known as Trk-C) in A549 cells via the TGFβ-SMAD 
pathway [21]. At present, its role(s) in prostate cancer has 
not been fully investigated, although our previous study 
demonstrated that TSPX could inhibit the transactivation 
of androgen receptor (AR) on its target genes [22]. Since 
the functions of tumor suppressors could be cell type 
specific [23–25], it is important to examine the role(s) of 
TSPX in prostate cancer development and the associated 
mechanism(s) in oncogenesis.
TSPX is a homologue of the Y-encoded proto-
oncoprotein TSPY that exacerbates cancer cell growth in 
vitro and in vivo [26]. TSPX and TSPY harbor a conserved 
domain, termed SET/NAP domain, initially identified in 
the oncoprotein, SE translocation (SET, also known as 
TAF-Iβ) and the nucleosome assembly proteins (NAPs), 
but diverged at the flanking regions [27, 28]. The TSPX 
protein harbors 3 major domains, (i) a proline-rich domain 
in the N-terminus, (ii) the centrally located SET/NAP-
domain and (iii) a long Asp/Glu-rich acidic domain in 
the C-terminus (hereby designated as C-terminal acidic 
domain, CAD) [27, 28]. Although TSPX and TSPY genes 
evolved from a common ancestral gene, only TSPX 
possesses a proline-rich domain and the CAD [29, 30]. 
Significantly, we have demonstrated that the CAD is 
primarily responsible for contrasting functions between 
TSPX and TSPY. For example, both proteins interact 
with cyclin B via their respective SET/NAP-domain, but 
TSPY stimulates while TSPX inhibits the kinase activity 
of cyclin B/CDK1 complex [28]. The inhibitory domain 
has been mapped to the CAD of TSPX [28]. Further, 
we recently demonstrated that TSPX could interact and 
inhibit the transactivation activity of androgen receptor 
(AR) in a CAD dependent manner. TSPX overexpression 
represses the expression of AR target genes, including 
KLK2 and KLK3, in a prostate cancer cell line LNCaP 
[22]. Since AR plays fundamental roles in the initiation 
and progression of prostate cancer [31, 32], TSPX might 
work as a modular for androgen and AR activities in 
the prostate. TSPX is primarily located in the nucleus, 
and presumed to play a role in transcription. Hence, 
understanding the roles of TSPX, particularly its CAD, 
in general transcriptional regulation of gene expression 
will be essential to determine its contributions to prostatic 
oncogenesis and cancer progression.
To explore the above issues, we have examined 
the effects of overexpression of the full length and 
variant versions of TSPX in the prostate cancer cell 
line LNCaP, and determined the respective effects in 
cell viability, morphology and gene expression patterns 
using RNA-Seq strategy. The expression patterns were 
then compared with those of clinical prostate cancer 
specimens with high or low TSPX expression from the 
Cancer Genome Atlas (TCGA) dataset [33]. Our results 
showed that overexpression of TSPX and/or its variants 
affected cell proliferation, morphology and viability. 
Transcriptome analyses demonstrated that the expression 
levels of various cancer-drivers/oncogenes, including 
MYC and MYB, were negatively correlated with that of 
TSPX in both LNCaP cells and clinical prostate cancer 
samples. Specifically, the expressions of MYC and MYB 
were suppressed by TSPX in LNCaP cells in a CAD-
dependent manner. Our findings suggest that TSPX is a 
crucial X-linked tumor suppressor in prostate cancer and 
its CAD plays important roles in the downregulation of 
multiple cancer-drivers/oncogenes, and are novel targets 
for diagnosis and clinical treatment of prostate cancer.
RESULTS
TSPX is frequently downregulated in prostate 
cancer
To explore the expression patterns of TSPX in 
prostate cancer, we had analyzed its expression levels 
in 15 paired samples of prostate cancer (T) and their 
adjacent non-tumor tissue (NT) by quantitative RT-
PCR (qRT-PCR). The result showed that TSPX was 
significantly downregulated in 9 cases (60%), while 
it was upregulated in 3 cases (20%) (Figure 1A and 
Table 1). Although the sample size was small to obtain a 
statistical significance, a general observation is that TSPX 
tends to be downregulated in prostate cancer. To verify 
the preliminary results of qRT-PCR analysis, we had 
datamined the RNA-Seq gene expression data of clinical 
prostate cancer samples downloaded from the Cancer 
Genome Atlas (TCGA) [33].  Of the 52 cases with tumor 
and non-tumor paired samples, TSPX was downregulated 
in 44 cases (83%) of prostate cancer, as compared to 
the adjacent normal specimens, and was up-regulated in 
6 cases (11%) (Figure 1B and Table 1), indicating that 
TSPX was significantly downregulated in prostate cancer 
of TCGA dataset (Wilcoxon matched pair test P-value < 
0.0001). These observations confirm those of qRT-PCR 
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analysis and suggest that TSPX expression might be 
involved in prostate cancer development.
Overexpression of TSPX induces morphological 
change and cell death in LNCaP cells
To explore the consequences of high TSPX 
expression in prostate cancer, various metastatic prostate 
cancer cell lines, e.g. LNCaP, PC3, and DU145, were 
analyzed with qRT-PCR strategy. Our results showed 
that TSPX expression was remarkably lower in these 
established prostate cancer cell lines than those of 
the primary prostate tissues (Figure 2A). Since the 
prostatic cancer cell lines are highly proliferative, these 
observations supported the postulation that TSPX 
expression is inversely correlated with cell proliferation 
and hence prostatic oncogenesis. To examine the effects 
of TSPX in prostatic cancer cells, the LNCaP cells were 
transduced with the tet-ON lentiviral vector system 
expressing EGFP and TSPX variants, i.e. TSPX[FL] 
with a longest N-terminal region or TSPX with a shorter 
N-terminal region (Δ26-108aa), under the control of 
doxycycline (Dox) (Figure 2B, 2C). The resultant cells 
were designated as LNCaP-tetON-TSPX[FL] and LNCaP-
tetON-TSPX, respectively. LNCaP-tetON-EGFP cells 
were used as a reference in these experiments. Western-
blot analyses confirmed that the expressions of TSPX[FL] 
and FLAG-tagged TSPX were appropriately controlled by 
Dox treatment (Figure 2D). Cell proliferation assays were 
performed at 0, 24, 48 and 72 hours. Our results showed 
that both TSPX[FL] and TSPX completely suppressed 
cell proliferation by 48 hours after Dox administration 
(Figure 2E). At 24 hour of transgene induction, the both 
LNCaP-tetON-TSPX[FL] and LNCaP-tetON-TSPX 
cells took on various round-shaped morphologies with 
cellular protrusions (Figure 2F), suggesting that TSPX-
overexpression could retard cell proliferation and induce 
cellular structural changes in LNCaP cells. Since TSPX 
lacks residue #26-108 at the N-terminus encompassing 
the proline-rich domain, the results also suggest that 
this domain is not critical for the cell proliferation and 
morphological functions. 
Scratch tests showed that the overexpression of 
TSPX led to dramatic morphological changes (Figure 
2G, 24 hr); and most cells detached from dish surface 
and floated in culture medium by 72 hours after Dox-
induction (Figure 2G, 72 hr), as compared to tetON-EGFP 
control cells. An Annexin-V binding assay showed that the 
floating cells were apoptotic/dead cells positively stained 
by Annexin-V (Figure 2H, red-stained cells). These 
observations suggest that high-level TSPX expression 
greatly inhibits cell proliferation and viability.
The C-terminal acidic domain of TSPX is crucial 
for induction of cell death and morphological 
change in LNCaP cells
Our previous studies demonstrated that the 
C-terminal acidic domain (CAD) of TSPX is critical for its 
tumor suppressor functions, such as suppression of cyclin 
Figure 1: The expression level of TSPX was frequently down-regulated in clinical prostate cancer. (A) Results of real-time 
qRT-PCR analysis of the TSPX expression levels in 15 prostate cancer tumor/non-tumor paired samples obtained from the Cooperative 
Human Tissue Network (CHTN). Expression values were normalized against GAPDH, and samples from the same patient are linked with 
a solid line respectively. Green indicate down-regulated cases, and red indicate up-regulated cases. Gray dotted lines indicate no significant 
change between non-tumor and tumor samples (P > 0.05). (B) Results of datamining of the RNA-Seq dataset from 52 prostate cancer 
tumor/non-tumor paired samples from the Cancer Genome Atlas (TCGA). Expression values (normalized count values) were plotted, and 
samples from the same patient are linked with a straight line as described above.
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B/CDK1 phosphorylation activities [28], degradation 
of a HBV viral oncoprotein HBx [34], and inhibition 
of the androgen receptor (AR) transactivation [22]. To 
explore the potential role of the CAD in regulation of 
cell proliferation and cell death in LNCaP cells, we had 
transduced the LNCaP cells with a TSPX variant with 
a truncated CAD (TSPX[ΔC]), designated as LNCaP-
tetON-ΔC cells, under the control of Dox (Figure 2B 
and 2C). Expression of TSPX[ΔC] in LNCaP-tetON-
ΔC cells was confirmed by western-blot (Figure 3A). 
Immunocytochemical analyses showed that both TSPX 
and TSPX[ΔC] were predominantly localized in the 
nuclei (Figure 3B). Cell proliferation assays unexpectedly 
showed that the overexpression of TSPX[ΔC] could also 
suppressed cell proliferation in LNCaP cells, similarly to 
those expressing TSPX transgene (Figure 3C, ΔC). The 
BrdU incorporation assays performed at 24 hours after 
Dox-induction demonstrated that the ratio of BrdU positive 
cells was significantly lower in both LNCaP-tetON-ΔC 
cells and LNCaP-tetON-TSPX cells than LNCaP-tetON-
EGFP reference cells with Dox-induction, suggesting that 
DNA synthetic activities were significantly repressed in 
TSPX or TSPX[ΔC] expressing cells (Figure 3D and 3E). 
However, overexpression of TSPX[ΔC] did not induce 
either morphological change or detachment from the 
growing surface (Figure 3F, tetON-ΔC). Further, LNCaP-
tetON-ΔC cells were rarely stained by Annexin-V at 48 
hours after Dox-induction (Figure 3G). These results 
suggest that TSPX could suppress cell proliferation, but 
its CAD is essential for induction of cell death and cellular 
morphological/structural changes in LNCaP cells.
High-level TSPX affected the gene expression 
patterns related with cell-viability and cell 
morphology in LNCaP cells
To explore the importance of CAD in TSPX 
functions in LNCaP cells, we performed RNA-Seq 
transcriptome analyses of both LNCaP-tetON-TSPX 
and LNCaP-tetON-ΔC cells with LNCaP-tetON-EGFP 
cells as controls using the Illumina RNA-Seq platform. 
The mRNAs were isolated from respective LNCaP cells 
in biological triplicates after Dox induction for 24 hours 
and subjected to RNA-Seq analysis. Genes representing 
changes with FDR< 0.001, Log2(gene expression level)>5, 
and |Log2(fold difference)|>0.8 were considered as 
differentially expressed genes (DEGs). The results showed 
that 1700 genes, including 818 upregulated genes and 
882 downregulated genes, were differentially expressed 
by TSPX-overexpression (Figure 4A and Supplementary 
Table 1). There were 2514 DEGs induced by TSPX[ΔC] 
overexpression, consisting of 1037 upregulated and 
1477 downregulated genes (Supplementary Table 1). 
To evaluate the effects of TSPX and the contribution of 
the CAD to its functions, the DEGs of the two groups 
were compared by plotting their differential expression 
levels (Supplementary Figure 1). There were 911 genes 
specifically affected by TSPX but not TSPX[ΔC], hereby 
designated as CAD-specific DEGs. There were 102 
genes inversely affected by TSPX and TSPX[ΔC], i.e. 
the gene expression changes were inverted in TSPX and 
TSPX[ΔC]-expressing cells, hereby designated as CAD-
inverted DEGs. In the present study, the CAD-specific 
DEGs and the CAD-inverted DEGs were combined and 
designated as the CAD-dependent DEGs for subsequent 
analyses, since CAD was critical for the gene expression 
changes of both groups. There were 98 genes affected 
by TSPX and to lesser extent by TSPX[ΔC], hereby 
designated as CAD-enhanced DEGs. There were 589 
genes affected by TSPX[ΔC] and to lesser extent by 
TSPX, hereby designated as CAD-independent DEGs 
since the presence of the CAD in TSPX was not required 
for the changes (Figure 4A, 4B, and Supplementary 
Table 2). In addition, 832 genes were affected only by 
TSPX[ΔC] specifically but not TSPX, hereby designated 
as TSPX[ΔC]-specific DEGs. 
To gain insights into the biological functions 
and pathways regulated by TSPX and the importance 
of the CAD in cellular properties associated with its 
overexpression in LNCaP cells, we had analyzed the CAD-
dependent, CAD-enhanced and CAD-independent DEGs 
with the Ingenuity Pathways Analysis (IPA) [22, 35, 36]. 
The results showed that the biological functions involved 
in cell viability and cell death were prominently affected 
by TSPX-overexpression in LNCaP cells (Figure 4C and 
Supplementary Table 3). In addition, genes associated 
with microtubule dynamics and cell-migration were also 
affected (Figure 4C and Supplementary Table 3). Sixty 
Table 1: Summary of the results of qRT-PCR analysis of CHTN RNA samples and data-mining of transcriptomes of 
TCGA datasets on paired tumor and non-tumor specimens (see Figure 1)
Sample NT > T NT = T NT < T Total (cases) P-value
CHTN 9
(60%)
3
(20%)
3
(20%)
15 0.1248
TCGA 44
(85%)
8
(15%)
52 <0.0001
NT > T: the TSPX expression level was lower in tumor sample (T) than the corresponding non-tumor sample (NT); NT = 
T: the TSPX expression level was similar between T and NT; NT < T: the TSPX expression level was higher in T than NT; 
P-value: Wilcoxon matched pair test P-value. 
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Figure 2: Overexpression of TSPX caused morphological changes and cell-death in LNCaP cells. (A) Comparison of the 
expression levels of TSPX among clinical prostate cancer samples and prostate cancer cell lines, LNCaP, PC3 and DU145. The expression 
levels were measured by qRT-PCR and normalized against GAPDH. (B) A schematic diagram of tet-ON system. In the presence of 
doxycycline (Dox), a transactivator rtTA is recruited on to the promoter region, and turns on the expression of transgene. (C) A diagrammatic 
illustration of transgene constructs for TSPX[FL], TSPX, and TSPX[ΔC]. (D) Western blot confirmed the expressions of EGFP and TSPX 
variants in the respective transduced LNCaP cells. β-actin was used as an internal and loading control. (E) Cell proliferation assay showed 
that expression of TSPX[FL] or TSPX (+Dox) inhibited cell proliferation, as compared to non-expressors (-Dox) or EGFP alone.  (F) Cell 
morphologies of LNCaP-tetON-TSPX and LNCaP-tetON-EGFP cells at 24 hours after transgene induction. The co-expression of EGFP 
was confirmed by immunofluorescence (green). The TSPX overexpression induced morphological changes to round shapes with dendrite-
like protrusions in LNCaP cells (arrows), but not EGFP alone. Far right panels show magnified images of the boxed area in the middle 
panels. (G) Scratch tests for LNCaP-tetON-TSPX cells (top) and LNCaP-tetON-EGFP cells (bottom) under transgene induction conditions. 
The morphology of LNCaP-tetON-TSPX cells dramatically changed by 24 hours, and numerous cells detached from the growing surface 
by 72 hours. (H) Annexin-V binding assay at 48 hours showed that the detached LNCaP-tetON-TSPX cells were positively stained by 
Annexin-V conjugated with Alexa Fluor 594 (red), corresponding to dead or apoptotic cells. Scale bar= 100 μm in F and H, 200 μm in G.
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Figure 3: Effects of truncation of the CAD from TSPX in LNCaP cells. (A) Western blots confirming the expressions of 
EGFP and FLAG-tagged TSPX variants in the respective transduced LNCaP cells. (B) Bright-field and immunofluorescence images 
of the FLAG-tagged TSPX variants (red), and DAPI staining (blue) in the respective transduced LNCaP cells at 24 hours after Dox-
induction. Far right panels show the merged images of anti-FLAG staining and DAPI staining in the boxed areas. (C) Cell proliferation 
assay showed that overexpression of TSPX or TSPX[ΔC] (+Dox) inhibited cell proliferation, as compared to non-expressers (-Dox) 
or EGFP alone. (D) Immunofluorescence of the BrdU incorporation (red) for LNCaP-tetON-EGFP cells and LNCaP-tetON-ΔC cells 
showed that cells overexpressing TSPX[ΔC] lacked DNA synthetic activities. (E) Quantified results of the BrdU incorporation assay. 
Bars indicate the percentage of BrdU-positive cells in the LNCaP-tetON-EGFP, LNCaP-tetON-TSPX, and LNCaP-tetON-TSPX[ΔC] 
population respectively. An asterisk indicates significance at P < 0.01. (F) Time dependent changes of LNCaP-tetON-TSPX cells (top) and 
LNCaP-tetON-ΔC cells (bottom) after Dox-induction of respective transgenes. Bright-field images of the same area at the indicated time 
points are presented. Far right panels show magnified images of the boxed area in the middle panels. (G) Annexin-V binding assay (red) at 
48 hours after  Dox-induction showed that only LNCaP-tetON-TSPX cells were positive for this apoptotic marker, but not LNCaP-tetON-
ΔC cells. EGFP green fluorescence in living cells are also presented on the left. Scale bar= 50 μm in B, 200 μm in E, 100 μm in F and G.
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to 70% genes of respective biological functions were 
affected by TSPX in a CAD-dependent manner (Figure 4C, 
red column) or a CAD-enhanced manner (Figure 4C, 
orange column), suggesting that CAD and possibly other 
domain(s) of TSPX might regulate respective genes 
involved in these functions and pathways. For example, 
the expression levels of tumor suppressor genes CDKN1A 
(also known as p21) and BAX were upregulated by 
TSPX[ΔC], indicating that these genes were upregulated 
in a CAD-independent manner (Figure 4D). In contrast, 
the oncogene MYC expression level was dramatically 
downregulated by TSPX (log2(fold change)= −1.609), 
while it was only slightly downregulated by TSPX[ΔC] 
(log2(fold change)= −0.370) (Figure 4D, top panels); 
indicating that the suppression of MYC expression 
was highly dependent on CAD. Western-blot analyses 
confirmed these results at the protein level, indicating 
that the CDKN1A and BAX proteins were increased 
by both TSPX[ΔC] and TSPX while the MYC protein 
was drastically decreased only by TSPX (Figure 4D, 
bottom panels). Although we cannot rule out any post-
transcriptional modifications affected by TSPX or 
TSPX[ΔC], the correlation of changes between transcripts 
and proteins of most DEGs suggests that the TSPX 
regulatory functions are likely to be at the transcription 
levels.
Correlation of the differentially expressed genes 
between the TSPX-overexpression in LNCaP 
cells and TSPX-high expression group of 
prostate cancer specimens
To correlate the effects of TSPX on cultured 
LNCaP cells to those of clinical prostate cancer, we had 
analyzed the transcriptomes of 497 clinical prostate cancer 
specimens from the TCGA database. The top 25 cases with 
the highest TSPX expression levels, hereby designated a 
TSPX-high group, were compared to those of 25 cases 
with the lowest TSPX expression levels, hereby designated 
as TSPX-low group (Figure 5A). The remainder of 447 
cases were designated as TSPX-mid  (middle expression 
level) group. The differentially expressed genes (DEGs) 
between TSPX-high and TSPX-low groups were selected 
with the criteria of false discovery rate FDR<0.005 and 
|Log2(fold difference)|>0.8 (Figure 5B and Supplementary 
Table 4). A total of 3146 DEGs between the two groups 
were identified and analyzed with IPA.  Our results showed 
that the TSPX expression level might be associated with 
activities of various pathways of cell movement, cell 
death/apoptosis, and organization of cytoskeleton (Figure 
5C and Supplementary Table 5). The association between 
the TSPX expression level and the pathways of cell 
death/apoptosis in clinical prostate cancer specimens was 
consistent with that in LNCaP cells (Figure 4C and 5C).
To identify the potential TSPX downstream gene in 
clinical prostate cancer, we had analyzed the differential 
gene expression patterns of LNCaP cells overexpressing 
TSPX versus EGFP (Figure 4A) and those of TSPX-high 
group versus TSPX-low group in clinical prostate cancer 
samples from TCGA datasets (Figure 5B). The DEGs with 
Student’s t-test P-value < 0.05 were used in the analysis to 
identify the downstream genes with stronger correlations. 
Our results showed that 166 DEGs were identified to 
share similar expression patterns associated with the 
TSPX expression level in both LNCaP cells and clinical 
prostate cancer specimens (Figure 5D and Supplementary 
Table 6). Out of these common 166 DEGs, 92 genes 
were CAD-dependent, 19 genes were CAD-enhanced, 
and 55 genes were CAD-independent DEGs (Figure 5E). 
Exploration by using CancerMine program [37] indicated 
many downregulated DEGs as caner-drivers/oncogenes, 
including MYC, MYB and AR (Supplementary Figure 2). 
Significantly, MYC, MYB and AR were downregulated 
by TSPX in a CAD-dependent manner in LNCaP cells 
(Figures 4D and 5F). In contrast, the upregulated DEGs 
included both caner-drivers/oncogenes, e.g. FGFR1 and 
MAP3K8, and tumor suppressors, e.g. SEMA3B and 
BTG2 (Supplementary Figure 2). SEMA3B and BTG2 
were upregulated by TSPX in either CAD-independent 
or CAD-enhanced manner in LNCaP cells (Figure 5F). 
Interestingly, CDKN1A and BAX were upregulated 
by TSPX-overexpression in LNCaP cells (Figure 4D), 
but not in TSPX-high clinical prostate cancer samples 
(Supplementary Table 4). Since various factors are 
involved in regulations of CDKN1A and BAX genes 
respectively [38, 39], the effect(s) of TSPX on these genes 
could potentially be minimized by other factors and/or 
cancer heterogeneity. 
To further explore the roles of TSPX in non-tumor 
prostate and the dosage dependent effects of TSPX in 
prostate cancer, the expression levels of tumor suppressors, 
SEMA3B and BTG2, and caner-drivers/oncogenes, MYC, 
MYB and AR, were compared among non-tumor prostate, 
TSPX-low prostate cancer, TSPX-mid prostate cancer, and 
TSPX-high prostate cancer samples. Our results showed 
that the expression levels of SEMA3B and BTG2 in the 
TSPX-high prostate cancer samples were similar with 
those in the non-tumor prostate samples (P-value > 0.05), 
while those in TSPX-low prostate cancer samples were 
significantly low (Figure 5G). On the other hand, the 
expression levels of MYC and MYB in TSPX-low prostate 
cancer samples were significantly higher than those in 
both non-tumor prostate samples and TSPX-high prostate 
cancer samples (Figure 5G). These results suggest that 
TSPX may play crucial roles to maintain the expressions 
of tumor suppressor genes, including SEMA3B and BTG2, 
and suppress oncogenes, such as MYC and MYB, in 
non-tumor prostate. Importantly, the expression levels of 
these genes were closely correlated with those of TSPX 
expression in the prostate cancer specimens, i.e. TSPX-
low, TSPX-mid, and TSPX-high respectively (Figure 
5G), suggesting that the regulatory effects of TSPX on 
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its targets in prostate cancer could be dosage dependent. 
The expression level of AR was lower only in TSPX-
high prostate cancer samples, and there was no significant 
difference between non-tumor prostate samples and TSPX-
low prostate cancer samples (Figure 5G), suggesting that 
AR could serve an essential function(s) not affected by 
TSPX in normal prostatic tissues. 
DISCUSSION 
TSPX has long been postulated as a tumor 
suppressor for lung cancer [17, 21], and numerous 
mutations have been demonstrated in various types of 
cancer [40, 41]. Although previous studies showed that 
it represses cell proliferation and negatively affects the 
cyclin B/CDK1 kinase activity and AR transactivation, its 
role(s) in prostate cancer has not been defined. The present 
study shows that the altered expression level of TSPX 
could be correlated with upregulation of various cancer-
drivers/oncogenes and repressions of tumor suppressors 
in both LNCaP cell line and clinical prostate cancer 
samples in a dosage dependent manner (Figure 5 and 
Supplementary Table 6). Since overexpression of TSPX 
retards cell proliferation and induces cell death in LNCaP 
cells (Figure 2), elevated levels of TSPX expression 
could be important for its tumor suppressor function(s) 
in prostate cancer. For example, the expression levels of 
cancer-drivers/oncogenes MYC, MYB, and AR, whose 
Figure 4: Comparative analysis of the transcriptomes of the LNCaP-tetON-TSPX and LNCaP-tetON-ΔC cells and 
identification of the CAD-dependent, CAD-enhanced, and CAD-independent differentially expressed genes (DEGs). 
(A) MA plots representing the gene expression changes mediated by TSPX-overexpression in LNCaP cells. Red plots indicate the CAD-
dependent DEGs, orange plots indicate the DEGs whose expression changes were enhanced by CAD (CAD-enhanced), and blue plots 
indicate the CAD-independent DEGs. Gray plots indicate non-differentially expressed genes (non-DEG). (B) Venn diagram showing the 
number of genes classified into the CAD-dependent, CAD-enhanced, and CAD-independent DEGs, respectively. (C) Results of Ingenuity 
Pathway Analysis (IPA) for DEGs mediated by TSPX-overexpression in LNCaP cells. Top ten biological functions identified among the 
DEGs are presented. A dark blue line indicates -log10(P-value) and bars indicate the numbers of DEGs associated with respective pathways. 
Bar colors indicate CAD-dependent (red), CAD-enhanced (orange), and CAD-independent (blue) DEGs respectively. (D, top panel) The 
relative expression levels of CDKN1A, BAX, and MYC in the Dox-induced LNCaP-tetON-EGFP (EGFP), LNCaP-tetON-ΔC (ΔC), and 
LNCaP-tetON-TSPX (TSPX) cells. Expression values are presented based on the normalized RNA-Seq count data (n = 3) (mean ± SEM). 
RSP20 was shown as an internal control. (D, bottom panel) Western-blot confirmed the corresponding protein expression of CDKN1A, 
BAX, and MYC in the Dox-treated LNCaP-tetON-EGFP, LNCaP-tetON-ΔC, and LNCaP-tetON-TSPX cells. Ratio values indicate the 
relative band-intensity normalized to RSP20 respectively.
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Figure 5: Identification of the consistent downstream genes of TSPX (TSPX-target genes) in both clinical prostate 
cancer samples and LNCaP cells. (A) Based on the TSPX expression level, prostate cancer cases were classified into the TSPX-high 
group (highest 25 cases), the TSPX-low group (lowest 25 cases), and TSPX-mid group (the remainder of 447 cases) of 497 prostate cancer 
specimens. (B) Volcano plot representing the DEGs between TSPX-high and TSPX-low prostate cancer groups (red plots) with a FDR < 
0.005. (C) Ingenuity Pathway Analysis (IPA) of DEGs between TSPX-high and TSPX-low expression level in prostate cancer. Top ten 
biological functions identified among the DEGs are presented. Red line indicates -log10(P-value) and bars indicate the numbers of DEGs 
associated with respective pathways. (D) A graph plotting the 166 TSPX-target genes whose expression levels (up or down) were consistently 
corresponded with those of TSPX in both clinical prostate cancer samples (X-axis) and LNCaP cells (Y-axis). Plot color indicates CAD-
dependent (red), CAD-enhanced (orange), and CAD-independent (blue), respectively. (E) Venn diagram summarizing the number of CAD-
dependent, CAD-enhanced, and CAD-independent TSPX-target genes. (F) The relative expression levels of SEMA3B, BTG2, MYB, and 
AR, in the Dox-induced LNCaP-tetON-EGFP, LNCaP-tetON-ΔC, and LNCaP-tetON-TSPX cells. Expression values are normalized RNA-
Seq count data (n = 3) (mean ± SEM). Asterisks indicate the Student’s t-test P-value < 0.05. (G) The gene expression patterns of TSPX- 
SEMA3B, BTG2, MYB, and AR, in clinical samples. Relative expression levels in non-tumor prostate tissues (NT), TSPX-low prostate 
cancer (PCa) group, TSPX-mid PCa group, and TSPX-high PCa group. Asterisk indicates the Student’s t-test P-value < 0.05. 
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roles in prostate cancer have been well established, were 
consistently lower in both TSPX-overexpressing LNCaP 
cells and TSPX-high clinical prostate cancer samples than 
the corresponding controls (Figure 5, and Supplementary 
Table 6).  In particular, MYC is an oncogene involved in 
the initiation and progression of various types of cancer 
through its collaborative functions with other cancer-
related genes [42, 43]. The high MYC expression level(s) 
is associated with poor clinical outcomes [44–46]. MYC 
is frequently upregulated in 70–90% of both prostatic 
intraepithelial neoplasia (PIN) and prostate cancer lesions, 
and the high-level MYC expression contributes to the 
initiation and progression of prostate cancer [47–50]. 
The prostate cancer susceptibility locus at Xp11.22 
has been identified with the SNP rs5945572 by a genome-
wide association study of 23,000 Icelanders and replicated 
with 15,500 European men [8] and American populations 
[51, 52]. At present, the exact nature of such susceptibility 
locus is still uncertain, although NUDT11, the gene 
most proximal to the rs5945572, has been implicated in 
such cancer predisposition [53]. As a tumor suppressor 
located at Xp11.22, TSPX could play a role in such cancer 
susceptibility. Similarly, another tumor suppressor gene, 
FOXP3, located at the Xp11.23 could also be involved. 
Knocking-down of FOXP3 results in an elevated MYC 
expression in human prostate epithelial cells (HPECs), and 
reactivation of FOXP3 expression downregulates MYC 
expression in prostate cancer cell lines [10]. Importantly, 
TSPX also downregulates MYC expression in both LNCaP 
cells (Figure 4D) and TSPX-high prostate cancer specimens 
(Figure 5G). Accordingly, the prostate cancer susceptibility 
locus at Xp11.2 could be related to the regulation of the 
MYC oncogene expression level. Inactivation and/or 
mutations of TSPX and/or FOXP3 tumor suppressors at 
the Xp11.2 locus might impair their regulatory functions on 
MYC expression, thereby exacerbating the susceptibility of 
prostate cancer initiation and progression. 
In addition to MYC, TSPX also represses MYB, 
an oncogenic transcription activator involved in the 
development of various malignant tumors including 
leukemia, colon cancer, and breast cancer, as well as prostate 
cancer [54–57]. It is frequently upregulated in the metastatic 
prostate cancer and contributes to the castration resistance 
[55, 56]. Accordingly, TSPX-dependent suppression 
of MYB expression could constitute part of its tumor 
suppressor functions in castration resistant prostate cancer. 
TSPX overexpression in LNCaP cells and TSPX-
high clinical prostate specimens are associated with 
elevated expression levels of two tumor suppressors 
SEMA3B and BTG2 (Figure 5, and Supplementary 
Table 6). SEMA3B is a secreted member of the 
semaphorin family, originally identified as a molecule 
for axonal guidance. Recent studies have revealed 
that SEMA3B could be a tumor suppressor in various 
cancer types, including lung cancer, breast cancer, and 
esophageal squamous cell carcinoma [58, 59]. High levels 
of SEMA3B expression are associated with better survival 
of prostate cancer patients [60]. BTG2 (also known as PC3 
or TIS21) is a member of TOB/BTG family participating 
in various anti-proliferative mechanisms [61–64]. BTG2 
is frequently downregulated in prostate cancer, and its 
reduced expression is correlated with development of 
castration-resistant prostate cancer [65, 66], suggesting 
that BTG2 plays an important role in suppression of 
prostate cancer progression. Our findings, therefore, 
support the role of TSPX as a tumor suppressor for 
prostate cancer via its actions in repressing the expression 
of various cancer-drivers/oncogenes and stimulating those 
of tumor suppressors.
As discussed, TSPX and its Y chromosome 
homologue, TSPY, evolved from the same ancestral 
gene, but diverged in functions on the modern-day sex 
chromosomes [27, 30]. So far, we demonstrated that the 
C-terminal acidic domain (CAD) of TSPX plays important 
roles in its inhibitory actions on the cyclin B/CDK1 kinase 
activity and the transactivation function of AR [22, 28]. 
Using different variants of TSPX, we showed that the 
proline-rich domain plays minimal role(s) in regulation of 
cell proliferation. Overexpression of TSPX[ΔC], a CAD-
truncated variant, was sufficient to arrest cell proliferation 
(Figure 3), while overexpression of TSPX could arrest cell 
proliferation and induce morphological/structural changes 
and eventually cell death (Figure 2). Comparative analyses 
of the transcriptomes of LNCaP-tetON-TSPX cells and 
LNCaP-tetON-ΔC cells revealed that a large number of 
the TSPX downstream genes were regulated in either 
CAD-dependent or CAD-enhanced manners, particularly 
pathway networks associated with cell viability and cell 
death in LNCaP cells (Figure 4). Importantly, the key 
cancer-drivers/oncogenes MYC, MYB and AR were 
suppressed by TSPX in a CAD-dependent manner (Figures 
4 and 5). In addition, other cancer-drivers/oncogenes, 
e.g. IGF1, CDK6 and PDK1 that are widely involved in 
oncogenesis [67–69], were also suppressed by TSPX in 
a CAD-dependent manner (Supplementary Figure 2 and 
Supplementary Table 2). These results strongly suggest 
that CAD is important for the tumor suppressor functions 
of TSPX at transcriptional regulation, i.e. downregulating 
various downstream cancer-drivers/oncogenes and 
stimulating other tumor suppressors. 
At present, the exact mechanism(s) of TSPX 
transcriptional regulation is still uncertain. Previously, 
we showed that TSPX interacts with AR and represses 
the AR transactivation of target genes [22]. Additional 
studies demonstrated that TSPX is an essential component 
of the REST/NRSF repressor complex, involved in 
transcriptional regulation of genes [21]. Further, it binds 
to the promoters of neuronal genes and regulates their 
expressions via histone modification in primary mouse 
neurons [70]. Although there would likely be different 
target genes between neurons and cancer cells, TSPX may 
be able to exert its transcriptional regulatory functions 
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via directly interaction and modulation on the promoter 
areas of its target genes (Figure 6). Indeed, a preliminary 
chromatin-immunoprecipitation (ChIP)-PCR assay of 
the Dox-induced LNCaP-tetON-TSPX cells and LNCaP-
tetON-ΔC cells showed that both TSPX and TSPX[ΔC] 
could bind to the MYC gene promoter, thereby confirming 
its direct bindings to the genes being regulated by TSPX 
(Supplementary Figure 3). 
Prostate cancer is highly heterogeneous cancer with 
significant variation in disease progression and mortality rate 
among the patients [71–73]. Hence, the clinical management 
of prostate cancer is still challenging in medicine [71, 72]. 
The present study demonstrates the importance of the 
CAD of TSPX in its tumor suppressor functions in prostate 
cancer and highlights the needs for further studies on TSPX-
mediated gene regulation, thereby providing novel insights 
in diagnosis and prognosis for clinical treatment and 
management of this common cancer in men.
MATERIALS AND METHODS
Quantitative reverse-transcription polymerase 
chain reaction analysis (qRT-PCR) of human 
prostate tissue samples
Snap frozen tissue samples of human prostate 
cancer (prostate cancer) and adjacent non-tumorous 
prostate were obtained from the Cooperative Human 
Tissue Network (CHTN) (http://www.chtn.nci.nih.gov/). 
Total RNA was extracted from 15 pairs of prostate cancer 
and corresponding adjacent non-tumorous prostate using 
Trizol reagent (Invitrogen, Carlsbad, CA), according 
to the manufacturer’s instructions. After RQ1-DNase 
treatment (Promega, Madison, WI) to remove any 
contaminant DNA, cDNA was synthesized from 1 μg 
total RNA using the Transcriptor Reverse Transcriptase 
kit with oligo(dT)15 primer (Roche Applied Science, 
Indianapolis, IN). The synthesized cDNA samples were 
individually analyzed in triplicates by quantitative real-
time PCR (qPCR) using the GoTaq qPCR Master Mix 
(Promega) and MyiQ real-time PCR detection system 
(Bio-Rad, Hercules, CA) as described previously [19]. 
The primer sequences were; glyceraldehyde 3–phosphate 
dehydrogenase (GAPDH) primers, 5′ -CCACCCA 
TGGCAAATTCCATGGCA-3′ and 5′ -TCTAGACGGCA 
GGTCAGGTCCACC-3′; TSPX primers, 5′-ACTTAC 
GGCAACAACTTCTTCAAA-3′ and 5′- AGGGCAAATG 
GGATAGTGGGTG-3′. The TSPX gene expression levels 
were normalized based on the corresponding levels of 
GAPDH in the same samples, and differential expression 
levels between tumor and non-tumorous sample pairs was 
then calculated and further analyzed with the Student’s 
t-test. Any differential expression level with P-value < 
0.05 was considered to be statistically significant. The 
expression level in cultured cell lines, LNCaP, DU145, 
and PC3, were measured similarly.
The human study was performed under an exempt 
protocol approved by the Institutional Committee on 
Human Research, VA Medical Center, San Francisco.
Plasmids and lentiviruses
Several TSPX variants were used in the present 
study: an isoform harboring the longest N-terminal 
Figure 6: A schematic diagram illustrating the likely mechanism(s) of the TSPX-mediated suppression of the MYC 
gene. TSPX interacts with the MYC promoter region via its SET/NAP domain, and the C-terminal acidic domain (CAD) plays an important 
role to suppress the MYC gene, likely by recruiting co-repressors to the promoter. Other cancer-drivers/oncogenes that were downregulated 
by TSPX may be also regulated in the similar manner(s).
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region, designated as TSPX[FL] (also called CDA1); a 
variant harboring shorter N-terminal segment, designated 
as TSPX, and a variant with a deleted CAD (397-693aa), 
designated as TSPX[ΔC] were used (Figure 2C) [34, 
74, 75]. The DNA fragments coding TSPX[FL] and 
FLAG epitope-tagged TSPX variants were extracted 
from the previously described plasmids, e.g. pcDNA3.1-
TSPX[full], p3xFLAG-TSPX[ΔPro] and p3xFLAG-
TSPX[ΔProΔC] [34], and inserted into pIRES2-EGFP 
vector (Clontech/Takara bio, Mountain View, CA), thereby 
adding a co-expressed EGFP at the 3’-end of the respective 
TSPX coding sequence. The bicistronic cassettes of 
TSPX-ires-EGFP were inserted into the FUW-tetO vector, 
respectively [76] (Addgene, Cambridge, MA), resulting 
in various FUW-tetO-TSPX expression vectors capable of 
expressing the respective TSPX variants and EGFP under 
the control of doxycycline (Dox) (Figure 2B). FUW-tetO-
EGFP was used as a negative control. The generation of 
replication-incompetent lentiviruses followed the methods 
previously reported [22, 76].
Cell culture
The human prostate adenocarcinoma cell lines, 
LNCaP, PC3 and DU145 were purchased from the 
American Type Culture Collections (ATCC, Manassas, VA) 
and cultured in RPMI 1640 medium containing 10% fetal 
bovine serum (FBS, Clontech) and antibiotics cocktail (100 
U/mL penicillin and 100 μg/mL Streptomycin; HyClone/
GE Healthcare Life Science). For doxycycline induction, 
LNCaP cells were cultured in the medium supplemented 
with tet system-approved fetal bovine serum (tetracycline-
free FBS, Clontech) and simultaneously transduced 
with lentiviral vectors, FUW-tetO-EGFP or FUW-tetO-
TSPX variants and the transactivator, FUW-M2rtTA. 
The transduced cells were cultured under non-induced 
conditions, in the absence of doxycycline (Dox). To induce 
the expression of TSPX and/or EGFP in the transduced 
cells, cells were cultured in the presence of 1 μg/mL Dox 
(Sigma-Aldrich). For cell proliferation analyses, cells 
were seeded at 2×103 cells/well in 96 well plates and 
cultured in the presence or absence of 1 μg/mL Dox. The 
cell viability was monitored at the indicated time points 
by using the CellTiter 96 Aqueous One Cell Proliferation 
Assay kit (Promega), a 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sul-fophenyl)-2H-
tetrazolium (MTS) based assay system, according to the 
manufacturer’s instructions. 
Western-blot
Western-blot was performed as described previously 
[34], using anti-FLAG mouse monoclonal IgG (clone M2, 
Sigma-Aldrich), anti-MYC rabbit monoclonal IgG (clone 
Y69, Abcam), anti-CDKN1A rabbit monoclonal IgG 
(clone EPR362, Abcam), anti-BAX rabbit monoclonal 
IgG (clone E63, Abcam), anti-RPS20 rabbit monoclonal 
IgG (clone EPR8716, Abcam), anti-βactin mouse 
monoclonal IgG (clone AC-15, Sigma-Aldrich), and anti-
TSPX rabbit IgG (against C-terminal region; Proteintech, 
Rosemont, IL). Immunoreactive signals were visualized 
by IRDye680RD conjugated anti-mouse IgG antibody or 
IRDye800CW conjugated anti-rabbit IgG antibody, and 
scanned by Odyssey system (LI-COR, Lincoln, NE). The 
band intensity was analyzed by using ImageJ software 
[77] (https://imagej.nih.gov/ij/).
Immunofluorescence
Immunofluorescence was performed as 
described previously [78]. Briefly, cells were fixed by 
4% paraformaldehyde-PBS solution for 5 min, and 
permeabilized by methanol treatment. After blocking by 3% 
bovine serum albumin (Sigma)-PBS solution for 1 hr, slides 
were incubated with primary antibodies at 4° C overnight. 
The primary antibodies used for immunofluorescence 
were anti-GFP goat IgG (Abcam) and anti-FLAG tag 
mouse monoclonal IgG. The immunoreactive signals were 
visualized by Alexa Fluor 594 conjugated anti-mouse 
IgG antibody and Alexa Fluor 488 conjugated anti-goat 
IgG antibody (Invitorgen). Nuclear DNA was visualized 
by staining with 4’,6-diamidino-2-phenylindole (DAPI) 
(Roche Applied Science). Fluorescent images of the living 
cells and immunofluorescence were recorded with a Nikon 
Eclipse Ti digital camera and image acquisition workstation 
(Nikon instrument Inc., Melville, NY). 
BrdU incorporation assay
Cells were seeded at 1.6 × 104 cells/well on 4 well 
chamber slides (Nunc Lab-Tek II CC2, Fisher Scientific) 
and cultured in the absence of Dox for 24 hours. 
Doxycycline at 1 μg/mL was then added in the medium to 
induce transgene expression. At 24 hours post-induction, 
cells were cultured with 10 μM 5-Bromo-2’-deoxyuridine 
(BrdU) (Sigma-Aldrich) for 2 hours, and fixed by 4% 
paraformaldehyde for 5 min. The cells labeled by BrdU 
were detected by immunofluorescence using anti-BrdU 
mouse monoclonal IgG (clone BU-1; GE Healthcare Life 
Sciences) as described above.
Annexin-V binding assay
Apoptotic and dead cells in culture were detected by 
Annexin-V binding assay using Alexa Fluor 594 conjugated 
Annexin-V (Invitrogen) and Annexin-V binding buffer 
(Invitrogen) according to manufacturer’s instructions. 
Fluorescent images were recorded as describe above.
Scratch test
The migratory properties and morphological 
changes were measured by a scratch wound assay [79]. 
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Briefly, cells were plated at 1×106 cells/10 cm dish and 
cultured for 48 hours in the absence of Dox. Before 
treatment with Dox, dishes were scratched with a 1000 μl 
pipette tip. Cells were cultured with fresh medium with or 
without 1 μg/mL Dox. Images of the scratched areas were 
recorded at 0, 24, 48, and 72 hours after scratching. 
RNA preparation and RNA-Seq transcriptome 
analysis for LNCaP cells
Total RNA was isolated from the LNCaP cells 
cultured in 6-well plates (9.6 cm2 surface area) at 24 
hours after Dox-induction using the TRIZOL-Plus RNA 
purification kit (Amnion/Thermo Fisher Scientific, NY). 
Each group was analyzed with biological triplicates with 
1 μg total RNA each. Combined mRNA purification 
and cDNA library preparations were performed with the 
KAPA Stranded mRNA-Seq kit (Kapa Biosystems, MA). 
Libraries were indexed with the NEBNext multiplex oligos 
for Illumina (New England Biolabs, CA). The libraries 
were subjected to 75-single end read cycles of sequencing 
on the NextSeq 500 (Illumina, CA). All procedures were 
performed according to the manufacturer’s instructions. 
After quality assessment by FastQC program [80], 
the sequence reads were mapped onto the human reference 
genome GRCh37/hg19 by using STAR [81]. The mapped 
reads were summarized and calculated to the count reads 
that could be associated with the expression levels using 
the featureCounts program [82]. Normalization of data and 
differential gene expression analysis were performed using 
TCC/edgeR software package [83].
Data source and data mining procedures
Gene expression data (level 3 RNA-Seq version 2) of 
prostate adenocarcinoma were downloaded from the Cancer 
Genome Atlas (TCGA) portal (http://cancergenome.nih.
gov), which included data of 52 tumor and non-tumor paired 
samples and 445 unpaired tumor samples, 497 prostate 
cancer samples in total.  Statistical analyses were performed 
using Prism6 program (GraphPad Software, Inc., La Jolla, 
CA) and Excel (Microsoft, Redmond, WA). Differentially 
expressed genes (DEGs) between two classified groups 
were identified using TCC/edgeR software package [83]. 
Gene expression enrichment analysis, functional 
network analyses and pathway analyses were performed 
by using Ingenuity Pathways Analysis (IPA) (build version 
463341M, QIAGEN) [22, 35, 36].
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